Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.

Autor: Hájek R; University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, 703 00, Czech Republic., Minařík J; Palacky University & University Hospital Olomouc, Olomouc, 771 47, Czech Republic., Straub J; General Teaching Hospital, Prague, 128 08, Czech Republic., Pour L; University Hospital, Brno, 625 00, Czech Republic., Jungova A; Faculty Hospital Pilsen, Pilsen, 301 00, Czech Republic., Berdeja JG; Sarah Cannon Research Institute, Nashville, TN 37203, USA., Boccadoro M; University of Torino, Torino, 10124, Italy., Brozova L; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Spencer A; Alfred Health-Monash University, Melbourne, 3004, Australia., van Rhee F; University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA., Vela-Ojeda J; UMAE Especialidades Centro Medico La Raza IMSS, Ciudad de México, 02990, Mexico., Thompson MA; Advocate Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI 53227, USA., Abonour R; Indiana University School of Medicine, Indianapolis, IN 46202, USA., Chari A; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Cook G; Leeds Teaching Hospital, Leeds, LS1 3EX, UK., Costello CL; Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA., Davies FE; Perlmutter Cancer Center, NYU Langone, New York, NY 10016, USA., Hungria VT; Clinica São Germano & Santa Casa Medical School, São Paulo, 04537-081, Brazil., Lee HC; M.D. Anderson Cancer Center, Houston, TX 77030, USA., Leleu X; Pôle Régional de Cancérologie, CHU de Poitiers, Poitiers, 86000, France., Puig N; Department of Hematology, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC (CB16/12/00233), Salamanca, 37007, Spain., Rifkin RM; Rocky Mountain Cancer Centers US Oncology Research, Denver, CO 80218, USA., Terpos E; National & Kapodistrian University of Athens, School of Medicine, Athens, 115 27, Greece., Usmani SZ; Levine Cancer Institute, Charlotte, NC 115 27, USA., Weisel KC; University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany., Zonder JA; Barbara Ann Karmanos Cancer Institute / Wayne State University School of Medicine, Detroit, MI 48201, USA., Bařinová M; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Kuhn M; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Šilar J; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Čápková L; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Galvez K; Hospital Pablo Tobón Uribe, Medellin, 11001, Colombia., Lu J; Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Beijing, 100044, China., Elliott J; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Stull DM; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Ren K; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Maisnar V; Charles University Hospital & Faculty of Medicine, Hradec Králové, 121 08, Czech Republic.
Jazyk: angličtina
Zdroj: Future oncology (London, England) [Future Oncol] 2021 Jul; Vol. 17 (19), pp. 2499-2512. Date of Electronic Publication: 2021 Mar 26.
DOI: 10.2217/fon-2020-1225
Abstrakt: Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov).
Databáze: MEDLINE